http://www.lctglobal.com/upload/news...ecruitment.pdf

Parkinson's trial resumes patient recruitment

Living Cell Technologies Limited has received the necessary regulatory approval to resume recruitment of the remaining three patients in the Phase I/IIa clinical trial of NTCELL® in Parkinson’s disease. The trial was paused in December last year while the company completed internal and external audit and regulatory processes.


Dr Ken Taylor, NTCELL Program Director and Acting Chief Executive, is pleased that patient recruitment in the clinical trial of NTCELL for Parkinson’s can resume.


“The completion of the clinical trial is an initial step in progressing NTCELL to commercialisation as the first disease modifying treatment for Parkinson’s disease.”